Clinical Trial

99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 4, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent imaging agent applicable to PSMA positive prostate cancer. This study will investigate the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for the diagnosis of lesions in PSMA positive prostate cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-14; most recent amendment 2025-05-29.
Status change: Not Yet Recruiting → Recruiting 2024-05-20
Trial Details
NCT Number NCT06419348
Lead Sponsor First Affiliated Hospital of Chongqing Medical University
Conditions Prostate Cancer Stage, PSMA, SPECT
Enrollment 30 participants
Start Date 2024-05-20
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-04